Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/efbICfbwoceYkCzRXLaM

January 11, 2013
Sign upForwardArchive
News for the PBM Industry

  Featured Story 
  • FDA demands dosage cuts for some sleep meds
    The FDA is ordering makers of brand-name and generic sedative-hypnotic drugs, or insomnia treatments with active ingredient zolpidem, to reduce dosages for women. Studies find that high levels of the drugs remain in the bloodstream, which can raise the risk of car accidents by affecting coordination and alertness. Dosages for regular products should be lowered from 10 milligrams to 5 milligrams, while dosages for extended-release formulations should be reduced from 12.5 milligrams to 6.25 milligrams. The Wall Street Journal/Dow Jones Newswires (1/10), The Seattle Times/The Associated Press (1/11) LinkedInFacebookTwitterEmail this Story
 Registration is now open for PCMA's Managed Markets Educational Forum!
Whether you are a seasoned managed markets executive or someone who supports the team, PCMA's Managed Markets Educational Forum will provide valuable education on fundamental, as well as complex and strategic issues relevant to professionals of all levels within pharma managed markets or market access divisions. Visit PCMA's website to learn more about our 2013 events!
 

  Legislative & Regulatory News 
  • Medicare cost growth remains low
    Growth in Medicare costs is historically low, according to a report from HHS, rising 0.4 percentage points per senior last year. Federal officials credited provisions in the Affordable Care Act, and other agencies say reductions in payments to insurers and providers will hold down cost increases for several years, but Republicans argue the measures mean doctors will eventually stop serving Medicare patients. The Hill/Healthwatch blog (1/10) LinkedInFacebookTwitterEmail this Story
  • CMS AMP rule could be finalized in Aug.
    The CMS rule on average drug manufacturer price is due to be finalized in August. It could lead to lower Medicaid pharmacy reimbursements in states that now overpay for generic drugs, Adam Fein writes. The proposed AMP rule is related to an Affordable Care Act provision instructing CMS to develop a new formula for determining the maximum pharmacy dispensing fees that a state Medicaid agency can reimburse. Drug Channels (1/10) LinkedInFacebookTwitterEmail this Story
  PBM Industry News 
  Drug Industry Spotlight 
  • Nonmedical use of Rx pain relievers varies between states
    An estimated 4.6% of people nationwide aged 12 and older engaged in nonmedical use of prescription pain relievers between 2010 and 2011, according to a report from the Substance Abuse and Mental Health Services Administration. Oregon recorded the highest rate of nonmedical use of pain medications, while Iowa had the lowest rate, researchers said. DoctorsLounge.com/HealthDay News (1/10) LinkedInFacebookTwitterEmail this Story
  SmartQuote 
The most valuable of all talents is that of never using two words when one will do."
--Thomas Jefferson,
3rd U.S. president


LinkedInFacebookTwitter

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

 
Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
 
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 
 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information